Natural Killer Cells

[Nature Communications] Scientists used a “two cell type” whole genome CRISPR-Cas9 screening system to discover key regulators of tumor sensitivity and resistance to natural killer cell-mediated cytotoxicity in human glioblastoma stem cells.

[Human Vaccines & Immunotherapeutics] Scientists investigated the effects of CYNK-001, human placental hematopoietic stem cell derived NK cells that exhibited strong cytolytic activity against a range of malignant cells and expressed high levels of activating receptors, against influenza A virus infections.

[Cytotherapy] Since Natural Killer (NK)-92 cells do not spontaneously express CCR7, clinical-grade activated NK cells were transfected with a non-viral vector containing the CCR7 receptor, an anti-CD19 CAR and a high-affinity CD16 Fc receptor.

[Artiva Biotherapeutics, Inc.] rtiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell therapies to treat cancer, announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada.

[Biomaterials] A dual pH-responsive hydrogel with tumor acidity neutralizer and neutrophil extracellular traps lyase was developed and used in combination with natural killer cell infusion for preventing post-resection hepatocellular carcinom recurrence.

[Cancer Cell International] The authors indicated a relationship between synaptosome associated protein 25 (SNAP25) expression and prostate cancer, demonstrating that SNAP25 was a potential prognostic biomarker due to its vital role in immune infiltration.